Press Release - Company Data

Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer
Posted 2014-07-22 00:03NAI Editing
today announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer under the revised clinical protocol

Halozyme Announces Clinical Hold of PEGPH20 Pancreatic Cancer Trial Following Voluntary Halt of Trial by Halozyme
Posted 2014-04-08 23:42NAI Editing
today announced that the United States Food and Drug Administration (FDA) informed the company yesterday that a clinical hold has been placed on patient enrollment and dosing of PEGPH20 in an ongoing

Halozyme Announces Temporary Halt Of Phase 2 Trial Enrollment And Dosing For PEGPH20
Posted 2014-04-03 22:42NAI Editing
today announced that as a result of a recommendation received yesterday from an independent Data Monitoring Committee (DMC), it is temporarily halting patient enrollment and dosing of PEGPH20 in an o

Halozyme Announces Positive Results From Phase 1/2 Clinical Trial In Cellulite With HTI-501
Posted 2014-03-24 23:21NAI Editing
today announced top-line data from a proof of concept Phase 1/2 clinical trial evaluating the use of HTI-501 in the treatment of cellulite.

Halozyme Announces Positive Opinion From CHMP For European Approval Of Roche's MabThera SC
Posted 2014-01-24 00:22NAI Editing
announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approve Roche's subcutaneous (SC) formulation of MabThera® (rituximab) us

Halozyme Secures Additional $20 Million Term Loan
Posted 2014-01-06 00:02NAI Editing
today announced it secured an additional $20 million loan from Oxford Finance and Silicon Valley Bank.

Halozyme Reports Third Quarter 2013 Financial Results
Posted 2013-11-08 00:22NAI Editing
today reported financial yu results for the third quarter and nine months ended September 30, 2013.

Halozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) Formulation with rHuPH20
Posted 2013-08-01 01:36NAI Editing
Halozyme HALO) announced that following discussions with the Center for Biologics Evaluation and Research (CBER) division of the U.S.

Halozyme Announces Positive Opinion from CHMP On Roche's Herceptin SC for European Approval
Posted 2013-06-28 01:40NAI Editing
announced today that Roche received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the subcutaneous formulation of Herceptin®

Halozyme's Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer
Posted 2013-06-02 23:30NAI Editing
today announced results from a Phase 1b trial of PEGPH20 (PEGylated Recombinant Human Hyaluronidase), an investigational new biologic, in combination with gemcitabine for the treatment of patients wit